Absence of ERR\(\alpha\) in Female Mice Confers Resistance to Bone Loss Induced by Age or Estrogen-Deficiency

Catherine Teyssier\(^1\), Marlène Gallet\(^1\), Bénédicte Rabier\(^2\), Laurent Monfoulet\(^2\), Julien Dine\(^3\), Claire Macari\(^1\), Julie Espallergues\(^3\), Béatrice Horard\(^4\), Vincent Giguère\(^5\), Martine Cohen-Solal\(^6\), Olivier Chassande\(^1\), Jean-Marc Vanacker\(^1\)*

\(^1\) Institut de Génomique Fonctionnelle de Lyon, Université de Lyon, Université Lyon 1, Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique, Ecole Normale Supérieure de Lyon, Lyon, France, \(^2\) Institut National de la Santé et de la Recherche Médicale, U 577, Université Victor Segalen Bordeaux II, Bordeaux, France, \(^3\) Institut National de la Santé et de la Recherche Médicale U710, Université de Montpellier II, Montpellier, France, \(^4\) Laboratoire de Biologie Moléculaire de la Cellule, CNRS UMR5239, Ecole Normale Supérieure de Lyon, Villeurbanne, France, \(^5\) The Rosalind and Morris Goodman Cancer Centre, Montréal, Canada, \(^6\) Institut National de la Santé et de la Recherche Médicale U606, Hôpital Lariboisière, Paris, France

Abstract

**Background:** ERR\(\alpha\) is an orphan member of the nuclear hormone receptor superfamily, which acts as a transcription factor and is involved in various metabolic processes. ERR\(\alpha\) is also highly expressed in ossification zones during mouse development as well as in human bones and cell lines. Previous data have shown that this receptor up-modulates the expression of osteopontin, which acts as an inhibitor of bone mineralization and whose absence results in resistance to ovariectomy-induced bone loss. Altogether this suggests that ERR\(\alpha\) may negatively regulate bone mass and could impact on bone fragility that occurs in the absence of estrogens.

**Methods/Principal Findings:** In this report, we have determined the *in vivo* effect of ERR\(\alpha\) on bone, using knock-out mice. Relative to wild type animals, female ERR\(\alpha\)KO bones do not age and are resistant to bone loss induced by estrogen-withdrawal. Strikingly male ERR\(\alpha\)KO mice are indistinguishable from their wild type counterparts, both at the unchallenged or gonadectomized state. Using primary cell cultures originating from ERR\(\alpha\)KO bone marrow, we also show that ERR\(\alpha\) acts as an inhibitor of osteoblast differentiation.

**Conclusion/Significance:** Down-regulating ERR\(\alpha\) could thus be beneficial against osteoporosis.

Citation: Teyssier C, Gallet M, Rabier B, Monfoulet L, Dine J, et al. (2009) Absence of ERR\(\alpha\) in Female Mice Confers Resistance to Bone Loss Induced by Age or Estrogen-Deficiency. PLoS ONE 4(11): e7942. doi:10.1371/journal.pone.0007942

Introduction

Bone is a highly dynamic tissue subjected to active remodeling, an equilibrium between construction by osteoblasts and resorption by osteoclasts. Osteoblasts are derived from mesenchymal stem cells (MSCs) and their differentiation is promoted by various factors such as the transcription factors Osterix and Runx2 [1–3]. Mature osteoblasts express receptor activator of nuclear factor-\(\kappa\)B ligand (RANKL), a protein that will signal through RANK, a member of the tumour necrosis factor receptor superfamily present at the surface of pre-osteoclasts, and induce differentiation of these cells [4–7]. On another hand, osteoclasts, as well as other cell types, also express and secrete osteoprotegerin (opg), a decoy receptor that traps RANKL in the extracellular milieu, preventing it from acting on pre-osteoclasts, and thus inhibiting the differentiation of osteoclasts [8,9].

Stability of bone remodeling also requires other diffusible factors among which estrogens are instrumental. This is particularly illustrated after menopause in aging women, when the fall of circulating level of estrogens leads to enhanced bone remodeling with an excessive resorption [10,11]. The resulting osteoporosis syndrome is associated with an enhanced fracture risk. Various means are currently available to prevent and treat osteoporosis, most of which mainly aim at inhibiting the excess of bone resorption. These include for example the use of estrogens (natural or synthetic) or of bisphosphonate to reduce osteoclast differentiation or induce their apoptosis, respectively [11].

The effects of estrogens are mediated by two estrogen receptors (ERs) \(\alpha\) and \(\beta\), which act as ligand-dependent transcription factors and belong to the nuclear receptor superfamily [12]. This family also comprises so-called orphan receptors, *i.e.* for which no ligand has been identified to date [13]. Estrogen-Receptor Related receptor \(\alpha\) (ERR\(\alpha\)) was among the first orphan receptors isolated, based on its sequence similarity to ER\(\alpha\) [14,15]. Despite this close proximity, ERR\(\alpha\) does not bind estrogen nor any identified natural ligand [16]. ERR\(\alpha\) is expressed in several tissues both
ERRα and Bone Loss

during embryonic development and in the adult [17]. A number of studies have identified ERRα as a major actor in the regulation of energy metabolism in oxidative tissues such as heart or slow-twitch skeletal muscle [18, 19 for reviews]. This receptor is indeed involved in the regulation of energy uptake, storage and consumption as well as in mitochondrial biogenesis and function and cardiac response to stress. Most of these effects are thought to depend on the PGC-1α coactivator, with which ERRα physically interacts. High expression of ERRα in various human tumors (originating from such organ as breast, colon and ovary) correlates with a poor prognosis [reviewed in 20]. Proliferation of various cancer cell lines can be inhibited by a synthesis modulator of ERRα, but not by its mere siRNA-mediated knocking-down [21].

ERRα is highly expressed in all ossification zones during mouse development, as well as in osteoblastic lines and normal human bones [22]. Furthermore, a polymorphic variant of the human ERRα promoter has been associated with variable bone mineral density (BMD) in premenopausal women [23]. Although the molecular functions of ERRα in bone cells have not been determined, osteopontin (opn), an inhibitor of bone mineralization [24–30], has been identified as a positive ERRα transcriptional target [31–33].

Here, we show that ERRα KO female mice resist to age-induced bone loss and present a more elevated bone formation rate as compared to wild type animals. Remarkably, ERRα deficiency also conferred resistance to bone loss induced by estrogen withdrawal. Noteworthy, no phenotype was observed in the bones of ERRα-deficient males. ERRα KO originating MSCs displayed enhanced capacities to differentiate into osteoblasts, together with a lower opn expression, as compared to wt MSCs. Altogether our results reveal the role of ERRα in the control of bone density and suggest important cross talks between ERRα and hormonal signalling pathways in bone physiology.

Results and Discussion

ERRα Deficiency Affects Bone Aging in Female, but Not in Male, Mice

The structural parameters of cortical and trabecular bone were measured in the femur diaphysis and metaphysis, respectively, of wild type (wt) and ERRα knockout female mice at 14 and 24 weeks. Cortical bone mineral density (BMD) and thickness augmented with age in a similar manner in both genotypes (Fig. 1A and B). The trabecular mineral density (TMD) was slightly more elevated (but not statistically significant) in wt animals as compared to ERRα KO, but significantly increased with time in the latter genotype (Fig. 1C). Lower trabecular bone volume (BV/TV; Fig. 1D) and trabecular number (TbN; Fig. 1E) were observed in ERRα KO animals relative to wt ones at 14 wk. Interestingly whereas these two parameters were significantly reduced at 24 wk in wt animals as an effect of age, no significant variation occurred in ERRα KO mice. These results indicate that ERRα KO female mice, although deficient in bone trabecular at maturity (14 wk), are resistant to age-related bone loss. Strikingly no difference was observed in any of the structural parameters of both cortical and trabecular bone between wild type and mutant male mice (Table 1), indicating a gender-dependent effect of the absence of ERRα.

The evolution of bone between wild type and ERRα KO females prompted us to examine the parameters of bone resorption and bone formation at 14 wk of age (i.e. before a significant difference could be observed between genotypes). Bone formation rate, which represent the activity of osteoblasts, was more elevated in ERRα KO females than in wt animals (Fig. 2A).

Figure 1. Bone phenotype of ERRα KO females mice. Cortical bone mineral density (BMD; A), cortical thickness (B), trabecular mineral density (TMD; C), bone volume fraction (BV/TV; D) and trabecular number (TbN; E) were determined at 14 (white bars) and 24 wk (black bars) in the femur of female wt and ERRα KO mice (n = 6 to 9). Errors bars represent s.e.m. ns: not significant; *p<0.005; *** p<0.005. doi:10.1371/journal.pone.0007942.g001

The surface occupied by osteoblasts was identical in both genotypes (Fig. 2B). Serum markers of bone resorption (C-terminal fragment of collagen 1 [Ctx], indicative of osteoclast activity) were not different between wild type and mutant females, indicating that bone resorption was not affected by the ERRα deficiency (Fig. 2C). Consistently, a comparable number of osteoclasts (Fig. 2D), spanning an identical relative surface (Fig. 2E) were detected in both strains.

Altogether this suggests that the resistance of ERRα KO animals to age-induced bone loss could be due to an enhanced osteoblastic activity, and not to variation in osteoclast-related parameters.
ERRα Negatively Regulates Osteoblast Differentiation

We thus analyzed the capacities of ERRαKO bone marrow mesenchymal cells to differentiate into osteoblasts ex vivo. After seven days in the appropriate medium, ERRα mutant cells produced a greater number of differentiation foci as estimated by alkaline phosphatase (ALP) staining (Fig. 3A). This was accompanied by a higher mineralization activity, as revealed by von Kossa staining. As measured by quantitative PCR, the expression of various osteoblast differentiation markers, such as Runx-2, ALP or osteocalcin was found more elevated in ERRαKO cells by quantitative PCR. In contrast, opn, an ERRα target gene [31–33], was less expressed in ERRαKO cells than in wild type cells. We also analyzed the kinetics of ALP expression during osteoblast differentiation (Fig. 3B). In ERRαKO cells, ALP expression followed the same profile as in wild-type cells but was more elevated at each time point. The phenotype displayed by mutant cells was rescued by infection with an ERRα-encoding adenovirus (AdERRα; Fig. 3C). Indeed, ALP staining was reduced by AdERRα infection as compared to cells infected with a GFP-encoding adenovirus. AdERRα also reduced the mRNA expression of Runx-2, ALP and osteocalcin. This repression was not a general, non-specific phenomenon since osteopontin expression was enhanced by AdERRα, as expected. This suggests that the capacities of MSCs to differentiate into osteoblasts are enhanced in the absence of ERRα and that the number of precursor cells is not modified. The results above may reflect an effect of the absence of ERRα on osteoblast proliferation rather than on differentiation.

To evaluate this hypothesis, we determined the growth capacities of bone marrow cells (Fig. 3D). ERRαKO cells displayed identical growth rate as wild-type cells, as estimated by determining cell number after 3 and 7 days in culture. However, under these conditions, ERRαKO cells still displayed a higher ALP expression as measured by staining and mRNA expression. We thus concluded that the absence of ERRα enhanced the osteoblastic differentiation of bone marrow cells without modifying their proliferation capacities. This is in agreement with recent results showing that the inhibition of ERRα expression in mammary cells does not modify proliferation [21]. Our results are in contrast with previous data suggesting that ERRα promotes osteoblast differentiation [34]. However, it is worth noting that our study analyzed femoral mesenchymal cells (which form endochondral bone, i.e. requiring a cartilage anlagen) derived from ERRαKO mice, whereas Bonnelye et al. [34] used transiently transfected rat calvarial cells (which form intramembranous bone). These methodological differences might account for the apparent discrepancies found between both studies. In contrast, our data are in agreement with published results in which MSCs originating from an independent ERRαKO strain were found more prone to differentiate into osteoblasts [35]. Interestingly this report also show that ERRα concomitantly promotes adipocyte differentiation of MSCs, suggesting that the receptor modulates an inverse relationship between adipogenic and osteogenic commitment of MSCs. In further support of our data, it is also worth noting that the closely related ERRγ receptor has recently been found to inhibit BMP2-induced osteoblast differentiation in vitro as well as BMP2-induced ectopic bone formation in vivo [36]. Elevated osteoblast differentiation in vitro in the absence of ERRα is furthermore consistent with the more elevated BFR found in vivo in ERRαKO mice. Furthermore, opn has been shown to inhibit bone mineralization [24–30]. A lower level of opn expression in the absence of ERRα could thus result in higher mineralization as observed in aging ERRαKO mice.

Table 1. Trabecular bone parameters of wt and ERRαKO male mice (n=8 to 10).

|                  | 14 wk |          | 24 wk |          | Orx1 |
|------------------|-------|----------|-------|----------|------|
|                  | wt    | ERRαKO   | wt    | ERRαKO   | wt   |
| TMD1 (mg/cc)     | 752 +/- 43 | 770 +/- 33 | 731 +/- 8 | 694 +/- 7 | 598 +/- 14 | 570 +/- 19 |
| BV/TV2 (%)       | 19.3 +/- 1.9 | 19 +/- 0.7 | 9.4 +/- 0.8 | 10 +/- 0.4 | 5.9 +/- 0.2 | 5.5 +/- 0.3 |
| TbN4 (mm)        | 7.7 +/- 0.6 | 7.5 +/- 0.4 | 4.7 +/- 0.3 | 4.5 +/- 0.5 | 3.6 +/- 0.3 | 3.9 +/- 0.3 |

1: orchidectomized animals.
2: trabecular mineral density.
3: bone volume/tissue volume.
4: trabecular number.
doi:10.1371/journal.pone.0007942.t001

ERRα Negatively Regulates Osteoblast Differentiation

We thus analyzed the capacities of ERRαKO bone marrow mesenchymal cells to differentiate into osteoblasts ex vivo. After seven days in the appropriate medium, ERRα mutant cells produced a greater number of differentiation foci as estimated by alkaline phosphatase (ALP) staining (Fig. 3A). This was accompanied by a higher mineralization activity, as revealed by von Kossa staining. As measured by quantitative PCR, the expression of various osteoblast differentiation markers, such as Runx-2, ALP or osteocalcin was found more elevated in ERRαKO cells by quantitative PCR. In contrast, opn, an ERRα target gene [31–33], was less expressed in ERRαKO cells than in wild type cells. We also analyzed the kinetics of ALP expression during osteoblast differentiation (Fig. 3B). In ERRαKO cells, ALP expression followed the same profile as in wild-type cells but was more elevated at each time point. The phenotype displayed by mutant cells was rescued by infection with an ERRα-encoding adenovirus (AdERRα; Fig. 3C). Indeed, ALP staining was reduced by AdERRα infection as compared to cells infected with a GFP-encoding adenovirus. AdERRα also reduced the mRNA expression of Runx-2, ALP and osteocalcin. This repression was not a general, non-specific phenomenon since osteopontin expression was enhanced by AdERRα, as expected. This suggests that the capacities of MSCs to differentiate into osteoblasts are enhanced in the absence of ERRα and that the number of precursor cells is not modified. The results above may reflect an effect of the absence of ERRα on osteoblast proliferation rather than on differentiation.

To evaluate this hypothesis, we determined the growth capacities of bone marrow cells (Fig. 3D). ERRαKO cells displayed identical growth rate as wild-type cells, as estimated by determining cell number after 3 and 7 days in culture. However, under these conditions, ERRαKO cells still displayed a higher ALP expression as measured by staining and mRNA expression. We thus concluded that the absence of ERRα enhanced the osteoblastic differentiation of bone marrow cells without modifying their proliferation capacities. This is in agreement with recent results showing that the inhibition of ERRα expression in mammary cells does not modify proliferation [21]. Our results are in contrast with previous data suggesting that ERRα promotes osteoblast differentiation [34]. However, it is worth noting that our study analyzed femoral mesenchymal cells (which form endochondral bone, i.e. requiring a cartilage anlagen) derived from ERRαKO mice, whereas Bonnelye et al. [34] used transiently transfected rat calvarial cells (which form intramembranous bone). These methodological differences might account for the apparent discrepancies found between both studies. In contrast, our data are in agreement with published results in which MSCs originating from an independent ERRαKO strain were found more prone to differentiate into osteoblasts [35]. Interestingly this report also show that ERRα concomitantly promotes adipocyte differentiation of MSCs, suggesting that the receptor modulates an inverse relationship between adipogenic and osteogenic commitment of MSCs. In further support of our data, it is also worth noting that the closely related ERRγ receptor has recently been found to inhibit BMP2-induced osteoblast differentiation in vitro as well as BMP2-induced ectopic bone formation in vivo [36]. Elevated osteoblast differentiation in vitro in the absence of ERRα is furthermore consistent with the more elevated BFR found in vivo in ERRαKO mice. Furthermore, opn has been shown to inhibit bone mineralization [24–30]. A lower level of opn expression in the absence of ERRα could thus result in higher mineralization as observed in aging ERRαKO mice.

![Figure 2. Dynamic parameters of ERRαKO female mice.](image-url)
ERRα Deficiency Protects Females from Bone Loss Resulting from Sex Hormone Ablation

Normal aging causes a moderate bone loss as the result of a progressive imbalance between bone formation and bone resorption. This equilibrium is also disrupted in favor of bone resorption upon sex hormone deficiency which leads to a severe bone loss, as can be observed in women after menopause or in mice after ovariectomy. Since bone formation is more elevated in ERRα KO we hypothesized that this phenomenon might compensate for the remodeling imbalance induced by sex-hormone withdrawal. Gonadectomized wild type females showed an important decrease of relative bone volume (Fig. 4A) and trabecular number (Fig. 4B) four wks after surgery. Strikingly, none of these parameters were significantly affected in ovariectomized ERRα KO animals, indicating that cancellous bone was preserved in mutant mice. Bone formation rate was enhanced in wt females as marker of enhanced bone remodeling (Fig. 4C). In contrast, this parameter did not vary in ERRα KO mice according to the hormonal status. In males, orchidectomy resulted in similar variations in mineral density, bone volume and trabecular number in wild type and mutant mice (Table 1), indicating suggesting that bone was equally affected, independently of the genotype. We thus concluded that the absence of ERRα completely protects against the bone loss induced by deficiency in sex hormone action in females, but not in males.

The mechanisms responsible for this phenomenon are not identified but it is tempting to speculate that i) the higher differentiation capacities of MSCs in osteoblasts in the absence of ERRα as well as ii) the low expression of opn in ERRα KO osteoblasts could be involved in sparing bone under estrogen...
deficiency challenge. Indeed, it has been shown that oop-deficient mice are resistant to ovariectomy-induced bone loss [37].

In summary, our data show that the absence of ERRα leads to a resistance in age- as well as estrogen-deficiency-dependent bone loss exclusively in female mice. This finding may have important consequences for the treatment of osteoporosis following menopause, and will need careful investigation to unravel the mechanisms through which ERRα acts in osteoblast differentiation and bone mineralization in vivo.

Materials and Methods

Animals

ERRαKO animals have been described elsewhere [38]. All animal experiments were performed in the Plateau de Biologie Experimentale de la Souris (PBES; ENS Lyon) under Animal care procedures, conducted in accordance with the guidelines set by the European Community Council Directives (86/609/EEC) and approved by the local ethical committee. Animals were in C57black6 background and, except were stated, had access to food and water ad libitum. Mice were sacrificed by cervical dislocation at 10 a.m.

For surgery, animals were anesthetized with sodium pentobarbital. Testes were ligated and cut through an incision in the scrotum. Ovaries were removed through an incision in the flanks. Animals were sacrificed 4 wk after operation. Statistical significance was analyzed using one-way ANOVA.

X-ray Micro-Computed Tomography Analysis

3D microarchitecture of the femur was evaluated using a high-resolution (8 μm) microtomographic imaging system (eXplore Locus, GE, USA). A 3D region within the secondary spongosia in the proximal metaphysis of the femur was reconstructed, beginning 500 μm proximal to the growth plate and extending to 1.5 mm. Cortical bone was reconstructed from a 1 mm thick region of interest centered on the diaphysis, 5 mm distal from the proximal growth plate. Morphometric parameters were computed using the Advanced Bone Analysis Microview Software (GE).

Histomorphometric Analysis

For histological analyses, undecalcified bones were fixed, dehydrated in ethanol solutions at 4°C, and embedded in methyl-methacrylate according to standard protocols. For each femur, 7 μm thick longitudinal sections, parallel to the sagittal plane, were prepared. Bone sections were stained with von Kossa/ van Gieseon reagent, images were captured using a Nikon eclipse 80i microscope and analyzed using NIS Elements AR 2.30 software (Nikon). To determine bone formation parameters, calcein (10 mg/kg body weight) was injected to mice i.p. 5 and 2 d before sacrifice. Bone formation rate was calculated as interlabeled widths/interval time. To determine bone resorption parameters, sections were stained for tartrate-resistant acid phosphatase (TRAP). TRAP-positive multinucleated cells attached to bone were scored as osteoclasts and results were expressed as number of osteoclasts per trabecular bone perimeter. Bone-related degradation products from Collagen 1 (CtX) in serum were measured by immunoassay, using a RatLaps ELISA kit from Nordic Bioscience Diagnostics A/S (Herlev, Denmark), following the recommendations of the manufacturers. Measurements were performed after overnight fasting.

Bone Marrow Cultures

Primary MSCs were collected from bone marrow of femur and tibia of 12-week old mice and cultured in six-well dishes (4×10^6 cells/well) in MEMα containing 10% fetal calf serum with 100 U/ml penicillin G and 100 μg/ml streptomycin. For osteoblastic differentiation, after 5 d of culture the medium was supplemented with 50 μg/ml L-ascorbic acid and 10 mM β-glycerophosphate and replaced every 2 to 3 days for 3, 7, 14 or 21 days. Osteoblastic differentiation was evaluated by ALP staining and ALP enzymatic activity. For ALP staining, cells were rinsed twice with PBS, and then fixed with 4% (v/v) formaldehyde for 5 min. After 3 washes with H2O, cells were incubated 30 min with Fast Blue RR salt and Naphtol AS-MX Phosphate Alkaline solution 0.25% (Sigma Aldrich) in the dark. For ALP enzymatic activity measurement, cells were lysed with Lysis Buffer (50 mM Tris, HCl pH 7.5; 0.1% Triton-X100; 0.9% NaCl). Cell lysates were incubated with 0.2 M of Naphtol Alkaline solution (Sigma Aldrich) and the conversion of p-nitrophenyl phosphate to p-nitrophenol was spectrophotometrically determined and normalized to cellular protein content by using detergent compatible Bradford reagent (Pierce). For proliferation tests, viable cells were visually counted after resuspension and trypan blue coloration. Adenoviral vectors expressing GFP or ERRα have been previously described [39] and kindly donated by Anastasia Krali.

Expression Analysis

RNAs were purified using Guanidinium thiocyanate/phenol/ chloroform extraction. Total RNAs were reverse transcribed using Superscript II retrotranscription kit (Invitrogen). Quantitative PCR were performed using the SYBR GREEN Jump Start kit (Sigma Aldrich) in duplicate on an ABI apparatus using standard procedure. Expression data were normalized to the expression of the 36b4 housekeeping gene. Sequence of the primers used in this study:

| Primer        | Sense/ Antisense | Accession number |
|---------------|------------------|------------------|
| 36b4          | 5'-ACCTCTTCTCCTTTCCAGGCTTT-3' and 5'-CCCACCTTCTCCAGTCTTT-3' | T81661         |
| ALP           | 5'-GCCCTCCAGATCTTCTTGGCCAACAA-3' and 5'-GCAGAGCCTGCTGGTCCTTA-3' | T81661         |
| ERRα          | 5'-CAAAGCCGCCCTCTGCTGGCTTCTT-3' and 5'-ACGTCATGCTCCCTGGATG-3' | T81661         |
| OCN           | 5'-ACCTACAGAGTGCGAAGCC-3' and 5'-AGCGGGGAGCTTGTCGACT-3' | T81661         |
| OPN           | 5'-CTTGATGGGCGGACAAATG-3' and 5'-AGTGTGGTGTTGTCATGGCT-3' | T81661         |
| Runx2         | 5'-GAGCTGGCCGCAGGCGTATTTC-3' and 5'-GGAAGCTTGCGCTGGGCTCTGAA-3' | T81661         |
Acknowledgments

We thank Anastasia Kralli for the gift of adenovirus vectors. We thank the personnel of the PBES, ENS Lyon, for helping in performing animal experiments.

References

1. Ducy P, Zhang R, Geoffroy V, Rydall AL, Karsenty G (1997) Osf2/Chfra1, a transcriptional regulator of osteoblast differentiation. Cell 8: 747–754.
2. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, et al. (2002) The novel zinc finger-containing transcription factor osteX is required for osteoblast differentiation and bone formation. Cell 108: 17–29.
3. Komori T (2006) Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 99: 1233–1239.
4. Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5: 618–625.
5. Xing L, Schwarz EM, Boyce BF (2005) Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 208: 19–29.
6. Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Endocrinol Metab 12: 17–25.
7. Asagiri M, Takayanagi H (2006) The molecular understanding of osteoclast differentiation. Bone 40: 251–264.
8. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309–19.
9. Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473: 139–146.
10. Syed F, Khodla S (2004) Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun 326: 680–686.
11. Raiz LG (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115: 3318–3325.
12. Latorre V, Gromemeyer H (2002) The nuclear receptor factbook. Academic press San Diego.
13. Giguère V (1999) Orphan nuclear receptors: from gene to function. Endocr Rev 20: 689–725.
14. Giguère V, Yang N, Segui P, Evans RM (1988) Identification of a new class of steroid hormone receptors, a novel secreted protein involved in the regulation of bone density. Cell 89: 309–19.
15. Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473: 139–146.
16. Horard B, Vanacker JM (2003) Estrogen receptor-related receptors: orphan nuclear receptor Estrogen-receptor-Related Receptor (ERR) functions in PPARα coactivator 1α-(PGC-1α)-induced mitochondrial biogenesis. Proc Natl Acad Sci USA 100: 14211–14218.
17. Reinholt FP, Hultenby K, Oldberg A, Heingard D (1998) Osteopontin, a possible anchor of osteoblasts to bone. Proc Natl Acad Sci USA 95: 1473–1477.
18. Ross FP, Chappell JL, Alvarez JI, Sandor D, Butler WT, et al. (1995) Interactions between the bone matrix protein osteopontin and bone sialoprotein and the osteoclast integrin β3 subunit. J Biol Chem 268: 9901–9907.
19. Ishijima M, Ringling SR, Yamashita T, Tsuji K, Kurusawa H, et al. (2001) Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J Exp Med 193: 399–404.
20. Mosky AL, Spevak I, Paschalakis I, Doyy SD, McKee MD (2002) Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 71: 145–154.
21. Shapses SA, Ciferri M, Spevak I, Choudury H, Brittingham J, et al. (2003) Osteopontin facilitates bone resorption, decreasing bone mineral crystallinity and content during calcium deficiency. Calcif Tissue Int 73: 86–92.
22. Kurokazuo NB, Denhardt DT, Guerlo N, Mann AB (2007) Osteopontin deficiency and aging on nanomechanics of mouse bone. J Biomed Mater Res A 83: 136–144.
23. Vanacker JM, Delmarre C, Guo X, Lautet V (1998) Activation of the osteopontin promoter by the orphan nuclear receptor estrogen receptor related alpha. Cell Growth Differ 9: 1007–1014.
24. Mosky AL, Pettersson K, Gustafsson JA, Lautet V (1999) Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta. EMBO J 18: 4370–4379.
25. Delhon I, Gutzwiller S, Morvan F, Rangwala S, Wyder L, et al. (2009) Enhanced ERalpha activity inhibits cell proliferation. J Mol Endocrinol 43: 61–73.
26. Jeong BC, Lee YS, Park YY, Park ICH, Kim DK, et al. (2009) The orphan nuclear receptor ERRalpha activity inhibits cell proliferation. J Mol Endocrinol 43: 61–73.